Imugene Limited (ASX:IMU) is trading ~15 per cent higher at $0.061 (12:41 PM AEST) following the release of its Quarterly Activities and Cash Flow Report for the quarter ended 30th June 2020.
Below are the key highlights of June 2020 quarter results:
- Preclinical research related to Mimotope vaccines targeting immune checkpoint inhibitors was published in “Frontiers in Immunology” journal.
- Independent Data Monitoring Committee (IDMC) validated HER-Vaxx safety and recommended continuation of study without modification.
- Imugene received acceptances for two abstract presentations presented at the American Association for Cancer Research 2020 Annual Meeting.
Post the reporting period, the Company also attained Human Research Ethics Committee (HREC) approvals to initiate PD1-Vaxx‘s Phase I trial in Australia.
Imugene’s cash balance stood at $30.1 million as at 30th June 2020.
Which stock gained the most attention in 2019? Find out in our exclusive report on the much talked about lithium stocks which gained the most investor attention amidst the volatile and high drama electric vehicle market.
Read about the shift in the Electric Vehicle market in 2020 and the consequent focus on Lithium in our report.
Get an insight into the lithium prices and the trends. The supply glut kept the lithium prices in check. The escalated bilateral trade dispute between the United States and China significantly impacted the lithium chemical prices.
Understand the performance of mining companies. The lithium mining companies managed to sail through the turbulent white gold market by limiting the production in correspondence with the demand from the offtake partners.